Andreas du Bois

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · New England Journal of Medicine · 2016 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo et al. · The Lancet · 2003 · 1.2K citations

Medicine, Gynecology, Oncology +17

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

Andreas du Bois · JNCI Journal of the National Cancer Institute · 2003 · 1.1K citations · Full text

Medicine, Gynecology, Oncology +17

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

Troels K. Bergmann, Henrik Gréen, Charlotte Brasch‐Andersen et al. · European Journal of Clinical Pharmacology · 2011 · 76 citations

Medicine, Oncology, Pharmacology +17

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer

Kate Lawrenson, Qiyuan Li, Siddhartha Kar et al. · Nature Communications · 2015 · 71 citations · Full text

Life Sciences, Genetics, Oncology +17